S-adenosylmenthionine decarboxylase as an enzyme target for therapy

Anthony Pegg, Peter P. McCann

Research output: Contribution to journalReview article

94 Citations (Scopus)

Abstract

The polyamine biosynthetic pathway has attracted much interest as a therapeutic target. Many studies have shown the potential value of inhibitors of the first enzyme in the biosynthetic pathway, ornithine decarboxylase, which forms putrescine. In order to convert putrescine into the polyamines, spermidine and spermine, the aminopropyl donor, decarboxylated S-adenosylmethionine, is needed. Therefore, S-adenosylmethionine decarboxylase (AdoMetDC, EC 4.1.1.50) is essential for polyamine synthesis. Early studies of the inhibition od this enzyme were carried out with compounds such as methylglyoxal bis(guanylhydrazone) that lack specificity and also lack potency since they are competitive inhibitors whose effects are overcome by a compensatory increase in the amount of the target enzyme. Recently, powerful irreversible inhibitors of AdoMetDC have become availab;e including 5′-{[(Z)-4-amino-2-butenyl]methylamino}-5′-deoxyadenosine an enzyme activated inhibitor and 5′-deoxy-5′-[(3-hydrazinopropyl)methylamino]adenosine which binds to the active site and forms a covalent bond with the pyruvate prosthetic group. This review describes the current state of knowledge of the structure and properties of AdoMetDC, the available inhibitors of this enzyme, their mechanism of action and their effects on polyamines and on the growth of tumors and protozoan parasites. These effects indicate that AdoMetDC inhibitors may be of therapeutic value either alone or in combination with ornithine decarboxylase inhibitors and that further trials of these compounds should be considered.

Original languageEnglish (US)
Pages (from-to)359-377
Number of pages19
JournalPharmacology and Therapeutics
Volume56
Issue number3
DOIs
StatePublished - Jan 1 1992

Fingerprint

Enzyme Therapy
Carboxy-Lyases
Polyamines
Enzyme Inhibitors
Putrescine
Biosynthetic Pathways
Mitoguazone
Adenosylmethionine Decarboxylase
Ornithine Decarboxylase
Spermidine
Spermine
Enzymes
Pyruvic Acid
Catalytic Domain
Parasites
Therapeutics
Growth
Neoplasms

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{203ddb7bc04b486297940416c129e6d9,
title = "S-adenosylmenthionine decarboxylase as an enzyme target for therapy",
abstract = "The polyamine biosynthetic pathway has attracted much interest as a therapeutic target. Many studies have shown the potential value of inhibitors of the first enzyme in the biosynthetic pathway, ornithine decarboxylase, which forms putrescine. In order to convert putrescine into the polyamines, spermidine and spermine, the aminopropyl donor, decarboxylated S-adenosylmethionine, is needed. Therefore, S-adenosylmethionine decarboxylase (AdoMetDC, EC 4.1.1.50) is essential for polyamine synthesis. Early studies of the inhibition od this enzyme were carried out with compounds such as methylglyoxal bis(guanylhydrazone) that lack specificity and also lack potency since they are competitive inhibitors whose effects are overcome by a compensatory increase in the amount of the target enzyme. Recently, powerful irreversible inhibitors of AdoMetDC have become availab;e including 5′-{[(Z)-4-amino-2-butenyl]methylamino}-5′-deoxyadenosine an enzyme activated inhibitor and 5′-deoxy-5′-[(3-hydrazinopropyl)methylamino]adenosine which binds to the active site and forms a covalent bond with the pyruvate prosthetic group. This review describes the current state of knowledge of the structure and properties of AdoMetDC, the available inhibitors of this enzyme, their mechanism of action and their effects on polyamines and on the growth of tumors and protozoan parasites. These effects indicate that AdoMetDC inhibitors may be of therapeutic value either alone or in combination with ornithine decarboxylase inhibitors and that further trials of these compounds should be considered.",
author = "Anthony Pegg and McCann, {Peter P.}",
year = "1992",
month = "1",
day = "1",
doi = "10.1016/0163-7258(92)90025-U",
language = "English (US)",
volume = "56",
pages = "359--377",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "3",

}

S-adenosylmenthionine decarboxylase as an enzyme target for therapy. / Pegg, Anthony; McCann, Peter P.

In: Pharmacology and Therapeutics, Vol. 56, No. 3, 01.01.1992, p. 359-377.

Research output: Contribution to journalReview article

TY - JOUR

T1 - S-adenosylmenthionine decarboxylase as an enzyme target for therapy

AU - Pegg, Anthony

AU - McCann, Peter P.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - The polyamine biosynthetic pathway has attracted much interest as a therapeutic target. Many studies have shown the potential value of inhibitors of the first enzyme in the biosynthetic pathway, ornithine decarboxylase, which forms putrescine. In order to convert putrescine into the polyamines, spermidine and spermine, the aminopropyl donor, decarboxylated S-adenosylmethionine, is needed. Therefore, S-adenosylmethionine decarboxylase (AdoMetDC, EC 4.1.1.50) is essential for polyamine synthesis. Early studies of the inhibition od this enzyme were carried out with compounds such as methylglyoxal bis(guanylhydrazone) that lack specificity and also lack potency since they are competitive inhibitors whose effects are overcome by a compensatory increase in the amount of the target enzyme. Recently, powerful irreversible inhibitors of AdoMetDC have become availab;e including 5′-{[(Z)-4-amino-2-butenyl]methylamino}-5′-deoxyadenosine an enzyme activated inhibitor and 5′-deoxy-5′-[(3-hydrazinopropyl)methylamino]adenosine which binds to the active site and forms a covalent bond with the pyruvate prosthetic group. This review describes the current state of knowledge of the structure and properties of AdoMetDC, the available inhibitors of this enzyme, their mechanism of action and their effects on polyamines and on the growth of tumors and protozoan parasites. These effects indicate that AdoMetDC inhibitors may be of therapeutic value either alone or in combination with ornithine decarboxylase inhibitors and that further trials of these compounds should be considered.

AB - The polyamine biosynthetic pathway has attracted much interest as a therapeutic target. Many studies have shown the potential value of inhibitors of the first enzyme in the biosynthetic pathway, ornithine decarboxylase, which forms putrescine. In order to convert putrescine into the polyamines, spermidine and spermine, the aminopropyl donor, decarboxylated S-adenosylmethionine, is needed. Therefore, S-adenosylmethionine decarboxylase (AdoMetDC, EC 4.1.1.50) is essential for polyamine synthesis. Early studies of the inhibition od this enzyme were carried out with compounds such as methylglyoxal bis(guanylhydrazone) that lack specificity and also lack potency since they are competitive inhibitors whose effects are overcome by a compensatory increase in the amount of the target enzyme. Recently, powerful irreversible inhibitors of AdoMetDC have become availab;e including 5′-{[(Z)-4-amino-2-butenyl]methylamino}-5′-deoxyadenosine an enzyme activated inhibitor and 5′-deoxy-5′-[(3-hydrazinopropyl)methylamino]adenosine which binds to the active site and forms a covalent bond with the pyruvate prosthetic group. This review describes the current state of knowledge of the structure and properties of AdoMetDC, the available inhibitors of this enzyme, their mechanism of action and their effects on polyamines and on the growth of tumors and protozoan parasites. These effects indicate that AdoMetDC inhibitors may be of therapeutic value either alone or in combination with ornithine decarboxylase inhibitors and that further trials of these compounds should be considered.

UR - http://www.scopus.com/inward/record.url?scp=0027097783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027097783&partnerID=8YFLogxK

U2 - 10.1016/0163-7258(92)90025-U

DO - 10.1016/0163-7258(92)90025-U

M3 - Review article

VL - 56

SP - 359

EP - 377

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 3

ER -